Last reviewed · How we verify
Administration of AVP
AVP is an arginine vasopressin analog that acts as a vasopressor agent to increase blood pressure and peripheral vascular resistance.
AVP is an arginine vasopressin analog that acts as a vasopressor agent to increase blood pressure and peripheral vascular resistance. Used for Hypotension in septic shock or critical illness, Variceal bleeding in portal hypertension.
At a glance
| Generic name | Administration of AVP |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Vasopressor agent |
| Target | V1 and V2 vasopressin receptors |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Intensive Care Medicine |
| Phase | Phase 3 |
Mechanism of action
AVP (arginine vasopressin, also known as antidiuretic hormone) binds to V1 and V2 receptors on vascular smooth muscle and renal collecting ducts, causing vasoconstriction and fluid retention. This mechanism is used therapeutically to treat hypotension and maintain hemodynamic stability in critical care settings.
Approved indications
- Hypotension in septic shock or critical illness
- Variceal bleeding in portal hypertension
Common side effects
- Peripheral vasoconstriction
- Hyponatremia
- Cardiac arrhythmias
- Mesenteric ischemia
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
- PARADIGM: Amplatzer Valvular Plug for PVL Closure (NA)
- Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Administration of AVP CI brief — competitive landscape report
- Administration of AVP updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI